In the Phase 2 trial against breast carcinoma and NSCLC, [18F]-ICMT-11 failed to demonstrate post-treatment changes in PET tumor signal, despite increased M30/M65 ratio in cytokeratin-18 analysis - a highly sensitive biomarker for caspase-3/7 activity. Here, CASP3 is linked to neoplasm.